Proteinuria and disease progression in the RaDaR IgAN cohort
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan is protective in thegddY mouse model of IgA nephropathy to a greater extent than losartan
Clinical Predictors of Major Adverse Kidney Disease Events in Patients with IgA Nephropathy
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Clinicopathological Characteristics of Adult IgA Nephropathy in the United States
SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy
SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design
EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases
FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results
Long-Term Outcomes in IgA Nephropathy Published in the CJASN